Genmab
GMAB
218 hedge funds and large institutions have $1.33B invested in Genmab in 2025 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 82 increasing their positions, 74 reducing their positions, and 36 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 74
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
4% more capital invested
Capital invested by funds: $1.28B → $1.33B (+$46.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 220 → 218 (-2)
36% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $1.72M
88.09% less ownership
Funds ownership: 98.03% → 9.94% (-88%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$45.4M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$42.8M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$13.3M |
| 4 |
Renaissance Technologies
New York
|
+$10.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$83.4M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$17.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$17.6M |
| 4 |
DP
DDD Partners
Bellevue,
Washington
|
-$11.8M |
| 5 |
Millennium Management
New York
|
-$9.91M |
GMAB Hedge Fund Activity: Q2 2025 in Review
218 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2025, worth a combined $1.33B — up 3.6% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new GMAB positions and 36 closed out — a net gain of 2 holders — while 82 added to existing stakes and 74 trimmed.
The largest buyer was Orbis Allan Gray, adding an estimated $45.4M. The largest seller was AllianceBernstein, cutting an estimated $83.4M.
- 218 institutional investors held Genmab (GMAB) as of Q2 2025, down from 220 in Q1 2025.
- Funds reported $1.33B of Genmab stock for Q2 2025, up 3.6% quarter-over-quarter.
- 38 funds opened new Genmab positions in Q2 2025 and 36 closed out, a net change of +2 holders.
- The largest Genmab buyer in Q2 2025 was Orbis Allan Gray, an estimated $45.4M added.
- The largest Genmab seller in Q2 2025 was AllianceBernstein, an estimated $83.4M sold.
Based on aggregated 13F filings for Q2 2025.